Effect of hypolipidemic drugs on cholinesterase activity in the rat

Kunec-Vajić, E.; Bernat, Nada; Muačević‐Katanec, Diana

doi:10.1016/0306-3623(92)90013-a

Cited by 3 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, fenofibrate increases paraoxonase activity [34] and increases ChE specific activity [35]. Clofibrate increases ChE activity [36], yet there have been inconsistent findings as to its effects on plasma paraoxonase activity [36,37].…”

Section: Resultsmentioning

confidence: 99%

Arylesterase Phenotype-Specific Positive Association Between Arylesterase Activity and Cholinesterase Specific Activity in Human Serum

Aoki

Helzlsouer

Strickland

2014

IJERPH

View full text Add to dashboard Cite

Context: Cholinesterase (ChE) specific activity is the ratio of ChE activity to ChE mass and, as a biomarker of exposure to cholinesterase inhibitors, has a potential advantage over simple ChE activity. Objective: To examine the association of several potential correlates (serum arylesterase/paraoxonase activity, serum albumin, sex, age, month of blood collection, and smoking) with plasma ChE specific activity. Methods: We analyzed data from 195 cancer-free controls from a nested case-control study, accounting for potential confounding. Results: Arylesterase activity had an independent, statistically significant positive association with ChE specific activity, and its magnitude was the greatest for the arylesterase phenotype corresponding to the QQ PON1192 genotype followed by phenotypes corresponding to QR and RR genotypes. Serum albumin was positively associated with ChE specific activity. Conclusions: Plasma arylesterase activity was positively associated with plasma ChE specific activity. This observation is consistent with protection conferred by a metabolic phenotype resulting in reduced internal dose.

show abstract

Section: Resultsmentioning

confidence: 99%

Arylesterase Phenotype-Specific Positive Association Between Arylesterase Activity and Cholinesterase Specific Activity in Human Serum

Aoki

Helzlsouer

Strickland

2014

IJERPH

View full text Add to dashboard Cite

show abstract

“…Our recent study, however, has shown that simvastatin significantly increases plasma and liver BuChE activity in normolipidemic rats (18). Fibrates have also been shown to increase BuChE activity in non-clinical studies (19,20). Clinical evidence, in turn, is still not strong enough to reach definitive conclusions about the effects of lipid-lowering agents on plasma BuChE activity (4,21).…”

mentioning

confidence: 93%

Effects of simvastatin and fenofibrate on butyrylcholinesterase activity in the brain, plasma, and liver of normolipidemic and hyperlipidemic rats

Vukšić

Lovrić

Konjevoda

et al. 2019

Archives of Industrial Hygiene and Toxicology

View full text Add to dashboard Cite

The study objective was to test the hypothesis that simvastatin and fenofibrate should cause an increase in butyrylcholinesterase (BuChE) activity not only in the plasma and liver but also in the brain of normolipidemic and hyperlipidemic rats. Catalytic enzyme activity was measured using acetylthiocholine (ATCh) and butyrylthiocholine (BTCh) as substrates. Normolipidemic and hyperlipidemic rats were divided in four groups receiving 50 mg/kg of simvastatin a day or 30 mg/kg of fenofibrate a day for three weeks and three control groups receiving saline. Simvastatin and fenofibrate caused an increase in brain BuChE activity in both normo- and hyperlipidemic rats regardless of the substrate. The increase with BTCh as substrate was significant and practically the same in normolipidemic and hyperlipidemic rats after simvastatin treatment (14–17% vs controls). Simvastatin and fenofibrate also increased liver and plasma BuChE activity in both normolipidemic and hyperlipidemic rats regardless of the substrate. In most cases the increase was significant. Considering the important role of BuChE in cholinergic transmission as well as its pharmacological function, it is necessary to continue investigations of the effects of lipid-lowering drugs on BuChE activity.

show abstract

Clinical and analytical considerations in the utilization of cholinesterase measurements

McQueen

1995

Clinica Chimica Acta

View full text Add to dashboard Cite

Effect of hypolipidemic drugs on cholinesterase activity in the rat

Cited by 3 publications

References 15 publications

Arylesterase Phenotype-Specific Positive Association Between Arylesterase Activity and Cholinesterase Specific Activity in Human Serum

Arylesterase Phenotype-Specific Positive Association Between Arylesterase Activity and Cholinesterase Specific Activity in Human Serum

Effects of simvastatin and fenofibrate on butyrylcholinesterase activity in the brain, plasma, and liver of normolipidemic and hyperlipidemic rats

Clinical and analytical considerations in the utilization of cholinesterase measurements

Contact Info

Product

Resources

About